Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jan;55(1):123-30.
doi: 10.1136/gut.2005.069757.

Steatosis in chronic hepatitis C: why does it really matter?

Affiliations
Review

Steatosis in chronic hepatitis C: why does it really matter?

T Asselah et al. Gut. 2006 Jan.

Abstract

Hepatic steatosis is a common histological feature of chronic hepatitis C. Various factors are associated with hepatic steatosis, including obesity, high alcohol consumption, diabetes type II, and hyperlipidaemia. These factors may contribute to steatosis in patients with chronic hepatitis C. In humans, hepatitis C virus (HCV) genotype 3 is more commonly associated with steatosis. In vitro studies and the transgenic mouse model have suggested that the HCV core protein (genotype 1) can induce lipid accumulation within hepatocytes. However, what is the relevance of steatosis in chronic hepatitis C? It seems that in certain populations, steatosis may be associated with fibrosis progression and this may be genotype specific. The mechanisms underlying this association are unknown; neither is it clear whether this holds true for all patients or only a subgroup. Indeed, after antiviral treatment, virus related steatosis disappears whereas the host associated steatosis remains unaffected. This review describes and discusses the basic and clinical aspects of the relationship between steatosis and progression of fibrosis, and response to treatment in patients with chronic hepatitis C.

PubMed Disclaimer

Comment in

  • Steatosis in chronic hepatitis C.
    Guidi M, Muratori P, Granito A, Muratori L, Lenzi M, Bianchi FB. Guidi M, et al. Gut. 2006 Jul;55(7):1047; author reply 1047-8. Gut. 2006. PMID: 16766755 Free PMC article. No abstract available.

Similar articles

Cited by

References

    1. Sanyal A J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 20021231705–1725. - PubMed
    1. Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease. Gastroenterology 20021221649–1657. - PubMed
    1. Neuschwander Tetri B A, Caldwell S H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003371202–1219. - PubMed
    1. Chitturi S, Farrell G C. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 20012127–41. - PubMed
    1. Kwiterovich P O., Jr The metabolic pathways of high‐density lipoprotein, low‐density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000865–10L. - PubMed

Publication types